Jounce Therapeutics Inc (JNCE)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

780 MEMORIAL DRIVE CAMBRIDGE, MA 02139

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.

Data as of 2021-09-19 13:07:45 -0400
Market Cap399.098 Million Shares Outstanding51.232 Million Avg 30-day Volume593.429 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.7514 52-week High/Low14.84 / 5.03 Next Earnings Date2021-11-04 Price to Cash FLow (P/CF) -86.8399
Data provided by IEX Cloud
View SEC Filings from JNCE instead.

View recent insider trading info

Funds Holding JNCE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding JNCE BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

THIRD ROCK VENTURES II, L.P.

THIRD ROCK VENTURES GP II, L.P.

TRV GP II, LLC

STARR KEVIN P

TEPPER ROBERT I

LEVIN MARK J

  • 10% Owner
3,332,638 2021-09-15 7

PFEFFER CARY

  • Director
50,468 2021-09-15 8

RAYTHATHA JIGAR

  • Director
0 2021-09-13 2

KARSEN PERRY A

  • Director
15,700 2021-06-18 1

DUNCAN BARBARA GAYLE

  • Director
15,700 2021-06-18 1

HIGGONS JOHN DUNCAN

  • Director
15,700 2021-06-18 5

KAMEN ROBERT

  • Director
15,700 2021-06-18 1

DIAZ LUIS

  • Director
15,700 2021-06-18 1

IANNONE ROBERT

  • Director
15,700 2021-06-18 1

SALTER-CID LUISA

  • Director
7,850 2021-06-18 3

TREHU ELIZABETH CHIEF MEDICAL OFFICER

  • Officer
909,110 2021-03-29 4

MURRAY RICHARD /CA/ CEO AND PRESIDENT

  • Officer
  • Director
222,871 2021-02-01 4

DRAPKIN KIMBERLEE C CFO AND TREASURER

  • Officer
65,431 2021-02-01 3

COLE HUGH M CHIEF BUSINESS OFFICER

  • Officer
73,889 2021-02-01 3

GILEAD SCIENCES INC

  • 10% Owner
5,539,727 2020-10-16 1

TEPPER ROBERT I

  • Director
  • 10% Owner
0 2020-06-26 0

CELGENE SWITZERLAND LLC

CELGENE CORP /DE/

  • 10% Owner
3,456,463 2017-02-01 0

THIRD ROCK VENTURES II, L.P.

THIRD ROCK VENTURES GP II, L.P.

TRV GP II, LLC

THIRD ROCK VENTURES III, L.P.

THIRD ROCK VENTURES GP III, L.P.

TRV GP III, LLC

LEVIN MARK J

STARR KEVIN P

  • 10% Owner
3,048,780 2017-02-01 0

HADLEY HARBOR MASTER INVESTORS (CAYMAN) L.P.

  • 10% Owner
No longer subject to file 2017-02-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

THIRD ROCK VENTURES II, L.P. - > 10% Owner

THIRD ROCK VENTURES GP II, L.P. - > 10% Owner

TRV GP II, LLC - > 10% Owner

STARR KEVIN P - > 10% Owner

TEPPER ROBERT I - > 10% Owner

LEVIN MARK J - > 10% Owner

2021-09-17 16:15:22 -0400 2021-09-15 J 1,750,000 d 2,697,829 direct yes 3.1873 3.1873 2 0.0 1

RAYTHATHA JIGAR - Director

2021-09-15 08:16:22 -0400 2021-09-13 A 31,400 a 31,400 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 22:15:03 UTC -0.1912 0.2612 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 21:45:03 UTC -0.1912 0.2612 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 21:15:03 UTC -0.1912 0.2612 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 20:45:03 UTC -0.2139 0.2839 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 20:15:03 UTC -0.2139 0.2839 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 19:45:03 UTC -0.2139 0.2839 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 19:15:03 UTC -0.2139 0.2839 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 18:45:04 UTC -0.2139 0.2839 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 18:15:03 UTC -0.2139 0.2839 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 17:45:03 UTC -0.2139 0.2839 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 17:15:03 UTC -0.2139 0.2839 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 16:45:03 UTC -0.1985 0.2685 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 16:15:03 UTC -0.1985 0.2685 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 15:45:03 UTC -0.1985 0.2685 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 15:15:03 UTC -0.1985 0.2685 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 14:45:03 UTC -0.251 0.321 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 14:15:03 UTC -0.251 0.321 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 13:45:03 UTC -0.251 0.321 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 13:15:03 UTC -0.251 0.321 950000
JOUNCE THERAPEUTICS INC JNCE 2021-09-23 12:45:03 UTC -0.251 0.321 950000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments